drugset / Trial / NCT04237428
CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma
Unknown
20 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Zhengzhou University · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor T cell infusion in the treatment of relapsed or refractory CD19 positive non-Hodgkin's lymphoma.
Timeline
- Start
- 2019-05-31
- Primary completion
- 2019-06-15
- Completion
- 2021-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T cells | Cell therapy | 500000 cells/kg | — |
| Subject | CD19 CAR-T cells | Cell therapy | 4e+06 cells/kg | — |
| Background | Acetaminophen | Small molecule | 30 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Diphenhydramine | Small molecule | 0.5 mg/kg | — |
| Background | Diphenhydramine | Small molecule | 1 mg/kg | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Promethazine | Small molecule | 25 mg | Intravenous |